Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 27, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,300,000 Ordinary shares of 25 pence each.
- Purchase Date: June 27, 2012.
- Price Range: Highest price paid was 1,485 pence per share; lowest price paid was 1,462 pence per share.
- Treasury Holdings (Settled): 473,157,927 shares (8.65% of total issued share capital).
- Treasury Holdings (Including Unsettled): 476,857,927 shares (9.55% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,994,056,889 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,300,000 shares, increasing the company's treasury stock holdings. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (473,157,927 settled vs. 476,857,927 including unsettled).
- Confirm the denominator for voting rights calculations is 4,994,056,889 shares.
- Check the average price paid per share against the reported range of 1,462 to 1,485 pence.
- Review the Annual General Meeting minutes from May 3, 2012, to confirm the scope of the repurchase authority.